Key Professional Analysts at BMO Capital Kept the Same their ‘Buy’ rating for Mylan Inc (NASDAQ:MYL) Shares Today. Their PT Given is $45.0

January 20, 2018 - By Marry Poplack

 Key Professional Analysts at BMO Capital Kept the Same their ‘Buy’ rating for Mylan Inc (NASDAQ:MYL) Shares Today. Their PT Given is $45.0

Investors sentiment decreased to 0.33 in Q3 2017. Its down 1.00, from 1.33 in 2017Q2. It worsened, as 3 investors sold Mylan N.V. shares while 0 reduced holdings. 1 funds opened positions while 0 raised stakes. 155,019 shares or 7.99% less from 168,486 shares in 2017Q2 were reported.

Gulf Interest Savings Bank (Uk) Ltd has invested 0.06% in Mylan N.V. (NASDAQ:MYL). Vantage Investment Advsr Lc holds 0.01% or 712 shares in its portfolio.

Mylan Inc (NASDAQ:MYL) Rating Reaffirmed

In a report made public on 30 October, The Buy rating of Mylan Inc (NASDAQ:MYL) shares was maintained by Analysts at BMO Capital, who now has a $45.0 target price on the stock. BMO Capital’s target price suggests a possible downside of -3.70 % from the current price of the company.

Investors sentiment decreased to 0.33 in Q3 2017. Its down 1.00, from 1.33 in 2017Q2. It worsened, as 3 investors sold Mylan N.V. shares while 0 reduced holdings. 1 funds opened positions while 0 raised stakes. 155,019 shares or 7.99% less from 168,486 shares in 2017Q2 were reported.

Gulf Interest Savings Bank (Uk) Ltd has invested 0.06% in Mylan N.V. (NASDAQ:MYL). Vantage Investment Advsr Lc holds 0.01% or 712 shares in its portfolio.

Mylan N.V. (NASDAQ:MYL) Ratings Coverage

Among 21 analysts covering Mylan Inc. (NASDAQ:MYL), 13 have Buy rating, 0 Sell and 8 Hold. Therefore 62% are positive. Mylan Inc. has $85 highest and $3000 lowest target. $49.62’s average target is 6.18% above currents $46.73 stock price. Mylan Inc. had 62 analyst reports since July 27, 2015 according to SRatingsIntel. The firm has “Hold” rating by RBC Capital Markets given on Friday, July 14. The rating was maintained by Wells Fargo with “Hold” on Thursday, January 18. The firm has “Buy” rating by Standpoint Research given on Wednesday, August 26. The stock has “Hold” rating by Cantor Fitzgerald on Thursday, December 21. The firm has “Buy” rating by Mizuho given on Wednesday, May 31. As per Thursday, January 4, the company rating was maintained by Citigroup. Cowen & Co downgraded the shares of MYL in report on Monday, July 27 to “Market Perform” rating. BTIG Research maintained the stock with “Buy” rating in Wednesday, August 19 report. The firm has “Buy” rating by Susquehanna given on Tuesday, November 7. The stock of Mylan N.V. (NASDAQ:MYL) has “Buy” rating given on Thursday, January 11 by Goldman Sachs.

The stock increased 0.47% or $0.22 during the last trading session, reaching $46.73. About 7.89 million shares traded or 30.29% up from the average. Mylan N.V. (NASDAQ:MYL) has declined 7.73% since January 20, 2017 and is downtrending. It has underperformed by 24.43% the S&P500.

Analysts await Mylan N.V. (NASDAQ:MYL) to report earnings on March, 7. They expect $1.40 EPS, down 10.83 % or $0.17 from last year’s $1.57 per share. MYL’s profit will be $751.02 million for 8.34 P/E if the $1.40 EPS becomes a reality. After $1.10 actual EPS reported by Mylan N.V. for the previous quarter, Wall Street now forecasts 27.27 % EPS growth.

Mylan N.V., together with its subsidiaries, develops, licenses, makes, markets, and distributes generic, brand name, and over-the-counter products worldwide. The company has market cap of $25.07 billion. The firm operates through three divisions: North America, Europe, and Rest of World. It has a 28.9 P/E ratio. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.

More recent Mylan N.V. (NASDAQ:MYL) news were published by: Streetinsider.com which released: “Momenta Phama (MNTA), Mylan NV (MYL) Announce Development Strategy for M710” on January 03, 2018. Also Bloomberg.com published the news titled: “Generic-Drug Firms Fall as US Threatens to Sue for Damages” on January 19, 2018. Seekingalpha.com‘s news article titled: “Goldman rates Mylan tops in generic drug space, sees 14% upside; shares ahead 3%” with publication date: January 11, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.